Jaguar Health, Inc. (JAGX)Healthcare | Biotechnology | San Francisco, United States | NasdaqCM
4.16 USD
-0.48
(-10.345%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 4.15 -0.01 (-0.010%) ⇩ (Oct. 13, 2026, 4:23 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 9:02 a.m. EDT
The immediate outlook is severely compromised by a catastrophic collapse in share price over the last two weeks, dropping from $34.46 to $4.79, which suggests a forced delisting or reverse split scenario rather than organic trading. This precipitous decline, combined with a trailing run of four consecutive years of negative annual returns and a century-long cumulative loss over nine years, indicates a business in terminal decline where the market has priced out all remaining value. Fundamentally, the company is bleeding cash with negative operating margins, shrinking revenues, and a debt load significantly exceeding its equity, while offering no dividend support. The recent news confirms this distress, highlighting desperate attempts to satisfy Nasdaq listing rules through reverse splits and stock dividends, alongside major dilution events. With no reliable earnings path and a balance sheet that cannot support operations, there is no case for holding or buying. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.304555 |
| AutoTheta | 0.304892 |
| AutoETS | 0.616751 |
| MSTL | 0.641319 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 18% |
| H-stat | 27.17 |
| Ljung-Box p | 0.016 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 4.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 253.286 |
| Revenue per Share | 1240.633 |
| Market Cap | 8,093,454 |
| Forward P/E | -0.73 |
| Beta | -0.11 |
| Profit Margins | -130.85% |
| Website | https://jaguar.health |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9958507 |
| Address1 | 200 Pine Street |
| Address2 | Suite 400 |
| All Time High | 1,313,490,990,000.0 |
| All Time Low | 2.35 |
| Ask | 5.5 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 5,506,630 |
| Average Daily Volume3 Month | 2,030,920 |
| Average Volume | 2,030,920 |
| Average Volume10Days | 5,506,630 |
| Beta | -0.105 |
| Bid | 4.17 |
| Bid Size | 1 |
| Book Value | 20.428 |
| City | San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.16 |
| Current Ratio | 0.739 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.41 |
| Day Low | 4.07 |
| Debt To Equity | 253.286 |
| Display Name | Jaguar Health |
| Dividend Date | 1,559,865,600 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,787,137,200 |
| Earnings Call Timestamp Start | 1,787,137,200 |
| Earnings Timestamp | 1,787,169,600 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -23,193,000 |
| Ebitda Margins | -0.83383006 |
| Enterprise To Ebitda | -0.622 |
| Enterprise To Revenue | 0.518 |
| Enterprise Value | 14,420,731 |
| Eps Forward | -5.68 |
| Eps Trailing Twelve Months | -4,012.65 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.4922 |
| Fifty Day Average Change | -5.3322 |
| Fifty Day Average Change Percent | -0.56174546 |
| Fifty Two Week Change Percent | -99.58507 |
| Fifty Two Week High | 1,260.0 |
| Fifty Two Week High Change | -1,255.84 |
| Fifty Two Week High Change Percent | -0.9966984 |
| Fifty Two Week Low | 2.35 |
| Fifty Two Week Low Change | 1.81 |
| Fifty Two Week Low Change Percent | 0.77021277 |
| Fifty Two Week Range | 2.35 - 1260.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,431,437,400,000 |
| Float Shares | 289,422 |
| Forward Eps | -5.68 |
| Forward P E | -0.73239434 |
| Free Cashflow | -1,778,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 47 |
| Fullday Change | -0.48999977 |
| Fullday Change Percent | -10.56034 |
| Fullday Price | 4.15 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.82308 |
| Gross Profits | 22,894,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0438 |
| Held Percent Institutions | 0.01766 |
| Implied Shares Outstanding | 1,945,542 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,789,603,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California. |
| Long Name | Jaguar Health, Inc. |
| Market | us_market |
| Market Cap | 8,093,454 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_12827020 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -52,420,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,633,984 |
| Open | 4.35 |
| Operating Cashflow | -6,685,000 |
| Operating Margins | -6.20163 |
| Payout Ratio | 0.0 |
| Phone | 415 371 8300 |
| Post Market Change | -0.009999752 |
| Post Market Change Percent | -0.24037866 |
| Post Market Price | 4.15 |
| Post Market Time | 1,791,923,027 |
| Previous Close | 4.64 |
| Price Hint | 4 |
| Price To Book | 0.20364206 |
| Price To Sales Trailing12 Months | 0.29097444 |
| Profit Margins | -1.3085 |
| Quick Ratio | 0.168 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.48000002 |
| Regular Market Change Percent | -10.344829 |
| Regular Market Day High | 4.41 |
| Regular Market Day Low | 4.07 |
| Regular Market Day Range | 4.07 - 4.41 |
| Regular Market Open | 4.35 |
| Regular Market Previous Close | 4.64 |
| Regular Market Price | 4.16 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 426,896 |
| Return On Assets | -0.3804 |
| Return On Equity | -5.48833 |
| Revenue Growth | -0.589 |
| Revenue Per Share | 1,240.633 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,945,542 |
| Shares Percent Shares Out | 0.0433 |
| Shares Short | 84,156 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 16,133 |
| Short Name | Jaguar Health, Inc. |
| Short Percent Of Float | 0.0433 |
| Short Ratio | 0.02 |
| Source Interval | 15 |
| State | CA |
| Symbol | JAGX |
| Total Cash | 3,788,000 |
| Total Cash Per Share | 10.994 |
| Total Debt | 16,651,000 |
| Total Revenue | 27,815,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4,012.65 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 156.22302 |
| Two Hundred Day Average Change | -152.06302 |
| Two Hundred Day Average Change Percent | -0.9733714 |
| Type Disp | Equity |
| Volume | 426,896 |
| Website | https://jaguar.health |
| Zip | 94,104 |